Throughout the last decades, dendritic cell (DC)-based anti-tumor vaccines have proven to
be a safe therapeutic approach, although with inconsistent clinical results. The functional …

Exploitation of the patient's own immune system to induce antitumor immune responses
using dendritic cell (DC) immunotherapy has been established in early clinical trials as a …

The past decade has seen tremendous developments in novel cancer therapies through the
targeting of tumor-cell-intrinsic pathways whose activity is linked to genetic alterations and …

Many approaches for cancer immunotherapy have targeted dendritic cells (DCs), directly or
indirectly, for the induction of antitumor immune responses. DC-based vaccines have been …

According to the GLOBOCAN reports, there were about 12.7 million cancer cases and 7.6
million cancer deaths in 2008, and the cancer burden continues to increase worldwide [1]. At …

The concept of DC‐based tumour vaccine has been tested both clinically and
experimentally for the past two decades. Even though only limited success has been …

Background Immunotherapeutic strategies to stimulate anti-tumor immunity are promising
approaches for cancer treatment. A major barrier to their success is the immunosuppressive …

Dendritic cells (DC) are specialized immune cells that play a critical role in promoting an
immune response against Ags, which can include foreign pathogenic Ags and self-tumor …

Importance of the field: Dendritic cells (DC) are powerful antigen-presenting cells that induce
and maintain primary cytotoxic T lymphocyte (CTL) responses directed against tumor …

The unique ability of dendritic cells to pick up antigens and to activate naive and memory
CD4+ and CD8+ T cells raised the possibility of using them to trigger a specific anti-tumor …